KRAS and non-small cell lung carcinoma: CfDNA analysis of a 67-year-old patient with KRASG12C-mutant NSCLC after progression on adagrasib showed a new (trans) KRASG12V mutation (11), coexisting with the (cis) KRASG12C mutation and probably arising from the wild-type KRAS allele.